InVivoSIM anti-human VEGF (Bevacizumab Biosimilar)
Catalog #SIM0007
Clone:
Bevacizumab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research use. This Bevacizumab biosimilar reacts with human VEGF (vascular endothelial growth factor). VEGF is a 45 kDa homodimeric, disulfide-linked glycoprotein that plays key roles in angiogenesis, vasculogenesis, and endothelial cell growth. It promotes mitogenesis, chemotaxis, and vascular permeability. Most tumors have a requirement for angiogenesis, and inhibition of VEGF biding to VEGF receptors has been the focus of several tumor therapeutic strategies. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the inhibition of tumor growth.Specifications
| Isotype | Human IgG1 |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Human VEGF |
| Reported Applications |
VEGF neutralization Flow Cytometry ELISA Immunoprecipitation Western Block |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
| Sterility | 0.2 Āµm filtration |
| Production | Purified from cell culture supernatant |
| Purification | Protein A |
| RRID | AB_2894728 |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |
Recommended Products
-
Recommended Isotype Control(s)
RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
-
Recommended Dilution Buffer
InVivoPure pH 7.0 Dilution Buffer
